Walvax Biotechnology Co., Ltd. (SHE:300142)

China flag China · Delayed Price · Currency is CNY
12.28
+0.22 (1.82%)
At close: Mar 16, 2026
Market Cap19.64B +0.1%
Revenue (ttm)2.40B -22.5%
Net Income49.24M -59.8%
EPS0.03 -59.8%
Shares Out1.60B
PE Ratio398.82
Forward PE75.57
Dividend0.03 (0.24%)
Ex-Dividend DateJan 9, 2026
Volume31,077,080
Average Volume28,512,452
Open12.18
Previous Close12.06
Day's Range12.12 - 12.33
52-Week Range9.70 - 14.65
Beta0.56
RSI54.07
Earnings DateMar 28, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The... [Read more]

Sector Healthcare
Founded 2001
Employees 2,388
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300142
Full Company Profile

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.

Financial Statements